Advertisement

Plasma cystatin-C and development of coronary heart disease: The PRIME Study

      Abstract

      The pathogenesis of ischemic coronary events involves degradation of the extracellular matrix in atherosclerotic lesions. The cysteine protease inhibitor cystatin-C may be involved in this phenomenon. The association of plasma cystatin-C with the incidence of myocardial infarction—coronary death and angina, was examined in a nested case–control (two controls per case) design within the prospective cohort study (Prospective Epidemiological Study of Myocardial Infarction (PRIME Study)) which included 9758 men aged 50–59 years who were free of coronary heart disease (CHD) on entry and followed for a 5-year period. Three hundred and thirteen participants suffered myocardial infarction or coronary death (n = 159) or angina pectoris (n = 154) during follow-up. Cystatin-C was positively correlated with body mass index (BMI), low-density lipoprotein (LDL)-cholesterol, triglycerides and several inflammatory markers such as fibrinogen (r = 0.18), C-reactive protein (CRP) (r = 0.24), interleukin-6 (=0.20), tumor necrosis factor-α (TNFα) (r = 0.27) and two TNFα receptors: TNFR1A (r = 0.43) and TNFR1B (r = 0.41); and negatively with high-density lipoprotein (HDL)-cholesterol (r = −0.25). After adjustment for traditional risk factors (age, diabetes, smoking, hypertension, BMI, triglycerides, LDL- and HDL-cholesterol), cystatin-C was significantly associated with the occurrence of the first ischemic coronary event. However, this association was no longer significant when CRP was included in the analysis. A decrease in glomerular filtration rate did not explain higher cystatin-C in cases than in controls. Cystatin-C appears to participate in the inflammatory phenomenon observed in the atherosclerotic process. Cystatin-C is not a more predictive risk marker of CHD than CRP or interleukin-6, but could be useful in detecting moderate chronic renal disease.

      Abbreviations:

      CHD (coronary heart disease), GFR (glomerular filtration rate), HDL (high-density lipoprotein), LDL (low-density lipoprotein), MI (myocardial infarction), PRIME Study (Prospective Epidemiological Study of Myocardial Infarction), RR (relative risk), TNF (tumor necrosis factor)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Shi G.P.
        • Sukhova G.K.
        • Grubb A.
        • et al.
        Cystatin C deficiency in human atherosclerosis and aortic aneurysms.
        J Clin Invest. 1999; 104: 1191-1197
        • Ducimetiere P.
        • Ruidavets J.B.
        • Montaye M.
        • Haas B.
        • Yarnell J.
        Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50–59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study.
        Int J Epidemiol. 2001; 30: 1057-1062
        • The PRIME Study Group
        The PRIME Study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland.
        Q J Med. 1998; 91: 667-676
        • Tunstall-Pedoe H.
        • Kuulasma K.
        • Amouyel P.
        • et al.
        Myocardial infarction and coronary deaths in the World Health Organization MONICA Project.
        Circulation. 1994; 90: 583-612
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Scarabin P.Y.
        • Arveiler D.
        • Amouyel P.
        • et al.
        Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study.
        Atherosclerosis. 2003; 166: 103-109
        • NKF
        K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.
        Am J Kidney Dis. 2002; 39: S76-S210
        • Cockcroft D.W.
        • Gault M.H.
        Prediction of creatinine clearance from serum creatinine.
        Nephron. 1976; 16: 31-41
        • Luc G.
        • Bard J.-M.
        • Juhan-Vague I.
        • et al.
        C-reactive protein, interleukin-6 and fibrinogen as predictors of coronary heart disease: the PRIME Study.
        Arterioscler Thromb Vasc Biol. 2003; 23: 1255-1261
        • Lindholt J.S.
        • Erlandsen E.J.
        • Henneberg E.W.
        Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms.
        Br J Surg. 2001; 88: 1472-1475
        • Albert M.A.
        • Rifai N.
        • Ridker P.M.
        Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis.
        Vasc Med. 2001; 6: 145-149
        • Faxon D.P.
        • Creager M.A.
        • Smith Jr., S.C.
        • et al.
        Atherosclerotic vascular disease conference: executive summary: atherosclerotic vascular disease conference proceeding for healthcare professionals from a special writing group of the American Heart Association.
        Circulation. 2004; 109: 2595-2604
        • Koenig W.
        • Twardella D.
        • Brenner H.
        • Rothenbacher D.
        Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate.
        Clin Chem. 2005; 51: 321-327
        • Galis Z.S.
        • Khatri J.J.
        Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.
        Circ Res. 2002; 90: 251-262
        • Eriksson P.
        • Deguchi H.
        • Samnegard A.
        • et al.
        Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease.
        Arterioscler Thromb Vasc Biol. 2004; 24: 551-557
        • Cimerman N.
        • Brguljan P.M.
        • Krasovec M.
        • Suskovic S.
        • Kos J.
        Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients.
        Clin Chim Acta. 2000; 300: 83-95
        • Kos J.
        • Krasovec M.
        • Cimerman N.
        • et al.
        Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis.
        Clin Cancer Res. 2000; 6: 505-511
        • Ridker P.M.
        • Hennekens C.H.
        • Buring J.E.
        • Rifai N.
        C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
        NEJM. 2000; 342: 836-843
        • Ridker P.M.
        • Rifai N.
        • Stampfer M.J.
        • Hennekens C.H.
        Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.
        Circulation. 2000; 101: 1767-1772
        • Cerne D.
        • Kaplan-Pavlovcic S.
        • Kranjec I.
        • Jurgens G.
        Mildly elevated serum creatinine concentration correlates with the extent of coronary atherosclerosis.
        Ren Fail. 2000; 22: 799-808
        • Matts J.P.
        • Karnegis J.N.
        • Campos C.T.
        • et al.
        Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. POSCH Group.
        J Fam Pract. 1993; 36: 497-503
        • Tonelli M.
        • Isles C.
        • Curhan G.C.
        • et al.
        Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
        Circulation. 2004; 110: 1557-1563
        • Laterza O.F.
        • Price C.P.
        • Scott M.G.
        Cystatin C: an improved estimator of glomerular filtration rate?.
        Clin Chem. 2002; 48: 699-707
        • Uhlmann E.J.
        • Hock K.G.
        • Issitt C.
        • et al.
        Reference intervals for plasma cystatin C in healthy volunteers and renal patients, as measured by the Dade Behring BN II System, and correlation with creatinine.
        Clin Chem. 2001; 47: 2031-2033